Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes
Small · 2023
DOI: 10.1002/smll.202301019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Lanxing Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Extracellular Vesicles. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes (T1D), which is a chronic autoimmune disease, results from the destruction of insulin‐producing β cells targeted by autoreactive T cells. The recent discovery that mesenchymal stem cell‐derived extracellular vesicles (MSC‐EVs) function as therapeutic tools for autoimmune conditions has attracted substantial attention. However, the in vivo distribution and therapeutic effects of MSC‐EVs potentiated by pro‐inflammatory cytokines in the context of T1D have yet to be established. Here, it is reported that hexyl 5‐aminolevulinate hydrochloride (HAL)‐loaded engineered cytokine‐primed MSC‐EVs (H@TI‐EVs) with high expression of immune checkpoint molecule programmed death‐legend 1 (PD‐L1) exert excellent inflammatory targeting and immunosuppressive effects for T1D imaging and therapy. The accumulated H@TI‐EVs in injured pancreas not only enabled the fluorescence imaging and tracking of TI‐EVs through the intermediate product protoporphyrin (PpIX) generated by HAL, but also promoted the proliferative and anti‐apoptotic effects of islet β cells. Further analysis revealed that H@TI‐EVs exhibited an impressive ability to reduce CD4 + T cell density and activation through the PD‐L1/PD‐1 axis, and induced M1‐to‐M2 macrophage transition to reshape the immune microenvironment, exhibiting high therapeutic efficiency in mice with T1D. This work identifies a novel strategy for the imaging and treatment of T1D with great potential for clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Nankai University, Tianjin, 300071, China.
- Department of Pharmacology, Tianjin Medical University, Tianjin, 300070, China.
- Key Laboratory of Radiopharmacokinetics for Innovative Drugs, Chinese Academy of Medical Sciences, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Ac…
- Department of Neurology, Tianjin Huanhu Hospital, Tianjin, 300350, China.
- College of Life Sciences, Nankai University, Tianjin, 300071, China.
- Institute of Transplant Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, 300192, China.
ORCID-Profile: Yuebing Wang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, L., Qi, C., Cao, H., Zhang, Y., Liu, X., Qiu, L., Wang, H., Xu, L., Wu, Z., Liu, J., Wang, S., Kong, D., & Wang, Y. (2023). Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes. Small. https://doi.org/10.1002/smll.202301019
Vancouver
Wang L, Qi C, Cao H, Zhang Y, Liu X, Qiu L, et al. Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes. Small. 2023. doi:10.1002/smll.202301019
BibTeX
@article{Wang2023,
author = {Wang, Lanxing and Qi, Chunxiao and Cao, Hongmei and Zhang, Yanwen and Liu, Xing and Qiu, Lina and Wang, Hang and Xu, Lijuan and Wu, Zhenzhou and Liu, Jianfeng and Wang, Shusen and Kong, Deling and Wang, Yuebing},
title = {Engineered Cytokine‐Primed Extracellular Vesicles with High PD‐L1 Expression Ameliorate Type 1 Diabetes},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202301019}
}
EUVIMED